2022 February 16
1.
S1P receptor modulators in Multiple Sclerosis: Detecting a potential skin cancer safety signal. Stamatellos VP, Rigas A, Stamoula E, Lallas A, Papadopoulou A, Papazisis G.
Mult Scler Relat Disord. 2022 Feb 9;59:103681. doi: 10.1016/j.msard.2022.103681. Online ahead of print.
PMID: 35168096
2.
A comprehensive review of varicella-zoster virus, herpes simplex virus and cryptococcal infections associated with sphingosine-1-phosphate receptor modulators in multiple sclerosis patients. Sharma K, Chaudhary D, Beard K, Srivastava S, Khalid SH, Sriwastava S.
Mult Scler Relat Disord. 2022 Feb 8;59:103675. doi: 10.1016/j.msard.2022.103675. Online ahead of print.
PMID: 35168095 Review.
3.
Distribution and relation of two arm function tests, Box and Blocks test and Nine Hole Peg test, across disease severity levels and types of multiple sclerosis. Bertoni R, Cattaneo D, Grosso C, Baglio F, Jonsdottir J.
Mult Scler Relat Disord. 2022 Feb 9;59:103683. doi: 10.1016/j.msard.2022.103683. Online ahead of print.
PMID: 35168094
4.
A novel disease specific scale to characterize the symptoms and impacts of fatigue in US adults with relapsing multiple sclerosis: A real-world study. Azoulai M, Lévy-Heidmann T, Morisseau V, Wilczynski O, Le HH, Jamieson C, Charvet LE, Krupp LB, Lair L.
Mult Scler Relat Disord. 2022 Jan 29;59:103637. doi: 10.1016/j.msard.2022.103637. Online ahead of print.
PMID: 35168093
5.
Brain grey matter perfusion in primary progressive multiple sclerosis: Mild decrease over years and regional associations with cognition and hand function. Testud B, Delacour C, El Ahmadi AA, Brun G, Girard N, Duhamel G, Heesen C, Häußler V, Thaler C, Has Silemek AC, Stellmann JP.
Eur J Neurol. 2022 Feb 15. doi: 10.1111/ene.15289. Online ahead of print.
PMID: 35167161
6.
Dietary habits, nutritional status and risk of a first demyelinating event: an incident case-control study in a southern European cohort. Cavalla P, Golzio P, Maietta D, Bosa C, Pasanisi MB, Alteno A, Schillaci V, Costantini G, Durelli P, Cuffini E, Panizzolo S, De Francesco A, Chiò A, Vercellino M.
Neurol Sci. 2022 Feb 15. doi: 10.1007/s10072-022-05908-0. Online ahead of print.
PMID: 35166977
7.
Sensor-based gait analyses of the six-minute walk test identify qualitative improvement in gait parameters of people with multiple sclerosis after rehabilitation. Berg-Hansen P, Moen SM, Austeng A, Gonzales V, Klyve TD, Negård H, Seeberg TM, Celius EG, Meyer F.
J Neurol. 2022 Feb 15. doi: 10.1007/s00415-022-10998-z. Online ahead of print.
PMID: 35166925
8.
The impact of the Australian Black Summer Bushfires and the COVID-19 pandemic on wellbeing in persons with multiple sclerosis; preparation for future and ongoing crises. Learmonth YC, Hunter A, Gibbs L, Walker D, Kermode AG, Marck CH.
Disabil Rehabil. 2022 Feb 15:1-14. doi: 10.1080/09638288.2022.2037756. Online ahead of print.
PMID: 35166613
9.
Bacillus Calmette-Guerin vaccination and multiple sclerosis: a population-based birth cohort study in Quebec, Canada. Corsenac P, Parent MÉ, Wolfson C, Arbour N, Duquette P, Benedetti A, Richard H, Stäger S, Rousseau MC.
Eur J Neurol. 2022 Feb 15. doi: 10.1111/ene.15290. Online ahead of print.
PMID: 35165983
10.
Cortical and white matter lesion topology influences focal corpus callosum atrophy in multiple sclerosis. Platten M, Ouellette R, Herranz E, Barletta V, Treaba CA, Mainero C, Granberg T.
J Neuroimaging. 2022 Feb 14. doi: 10.1111/jon.12977. Online ahead of print.
PMID: 35165979
11.
Characterizing the time course of cerebrovascular reactivity in multiple sclerosis. Lincoln JA, Hasan KM, Gabr RE, Wolinsky JS.
J Neuroimaging. 2022 Feb 14. doi: 10.1111/jon.12979. Online ahead of print.
PMID: 35165962
12.
Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study. Riccardo BA, Giulio V, Massimiliano C, Giovanna L, Valentina T, Paola C, Teresa MG, Diana F, Viviana N, Marta R, Chiara BM, Damiano P, Alberto G, Pietro A, Federica P, Massimiliano DF, Cinzia C, Emanuela Z, Riccardo S, Ivan G, Antonio S, Martina P, Marcello A, Vincenzo BM, Claudio S, Claudio G, Eleonora C, Marcello M, Roberta L; Raising Italian Researchers in Multiple Sclerosis (RIREMS) study group.
J Neurol. 2022 Feb 14. doi: 10.1007/s00415-022-11009-x. Online ahead of print.
PMID: 35165767
13.
Eagle Syndrome: A Rare Cause of Stroke in a Young Patient. Alobaidi HA, Alfaran AA, Algazwi HH, Alkhater FI, Alshooalah HM, Alanzi AK, Almindil IA, Alqasim AK, Faqeeh AA, Almutairi AA, Alnaqa GH, Alnaqa NH, Alasmari RM, Almashouf RM, Al-Hawaj F.
Cureus. 2022 Jan 11;14(1):e21102. doi: 10.7759/cureus.21102. eCollection 2022 Jan.
PMID: 35165561 Free PMC article.
14.
New oligodendrocytes exhibit more abundant and accurate myelin regeneration than those that survive demyelination. Neely SA, Williamson JM, Klingseisen A, Zoupi L, Early JJ, Williams A, Lyons DA.
Nat Neurosci. 2022 Feb 14. doi: 10.1038/s41593-021-01009-x. Online ahead of print.
PMID: 35165460
15.
The neuroprotective effects of icariin on ageing, various neurological, neuropsychiatric disorders, and brain injury induced by radiation exposure. Li LR, Sethi G, Zhang X, Liu CL, Huang Y, Liu Q, Ren BX, Tang FR.
Aging (Albany NY). 2022 Feb 14;14(undefined). doi: 10.18632/aging.203893. Online ahead of print.
PMID: 35165207
16.
Whole-Brain Metabolic Abnormalities Are Associated With Mobility in Older Adults With Multiple Sclerosis. Mueller C, Baird JF, Motl RW.
Neurorehabil Neural Repair. 2022 Feb 14:15459683221076461. doi: 10.1177/15459683221076461. Online ahead of print.
PMID: 35164595
17.
Thematic analysis of multiple sclerosis research by enhanced strategic diagram. Shafin N, Ismail CAN, Mustafa MZ, Ghani N, Ahmad AH, Othman Z, Wijaya A, Zakaria R.
Mult Scler. 2022 Feb 15:13524585221075542. doi: 10.1177/13524585221075542. Online ahead of print.
PMID: 35164590
18.
Targeting the neurological comorbidities of multiple sclerosis: the beneficial effects of VIP and PACAP neuropeptides. Jansen MI, Broome ST, Castorina A.
J Integr Neurosci. 2022 Jan 28;21(1):33. doi: 10.31083/j.jin2101033.
PMID: 35164469 Review.
19.
Neuropsychological correlates of cerebellar volumes in multiple sclerosis: an MRI volumetric analysis study. Iliadou P, Bakirtzis C, Ioannidis P, Possin K, Zygouris S, Sintila SA, Grigoriadis N, Aretouli E.
J Integr Neurosci. 2022 Jan 28;21(1):13. doi: 10.31083/j.jin2101013.
PMID: 35164449
20.
Clinical and neurophysiological patterns of impairments to emotion attention and empathy in multiple sclerosis. Adamaszek M, Krüger S, Kessler C, Hosten N, Hamm A.
J Integr Neurosci. 2022 Jan 28;21(1):7. doi: 10.31083/j.jin2101007.
PMID: 35164443
21.
Healthy Properties of a New Formulation of Pomegranate-Peel Extract in Mice Suffering from Experimental Autoimmune Encephalomyelitis. Vallarino G, Salis A, Lucarini E, Turrini F, Olivero G, Roggeri A, Damonte G, Boggia R, Di Cesare Mannelli L, Ghelardini C, Pittaluga A.
Molecules. 2022 Jan 28;27(3):914. doi: 10.3390/molecules27030914.
PMID: 35164175
22.
Kirenol: A Potential Natural Lead Molecule for a New Drug Design, Development, and Therapy for Inflammation. Nasir NN, Sekar M, Fuloria S, Gan SH, Rani NNIM, Ravi S, Begum MY, Chidambaram K, Sathasivam KV, Jeyabalan S, Dhiravidamani A, Thangavelu L, Lum PT, Subramaniyan V, Wu YS, Azad AK, Fuloria NK.
Molecules. 2022 Jan 23;27(3):734. doi: 10.3390/molecules27030734.
PMID: 35163999 Review.
23.
Identification of Corosolic and Oleanolic Acids as Molecules Antagonizing the Human RORγT Nuclear Receptor Using the Calculated Fingerprints of the Molecular Similarity. Pastwińska J, Karaś K, Sałkowska A, Karwaciak I, Chałaśkiewicz K, Wojtczak BA, Bachorz RA, Ratajewski M.
Int J Mol Sci. 2022 Feb 8;23(3):1906. doi: 10.3390/ijms23031906.
PMID: 35163824
24.
The Therapeutic Prospects of Targeting IL-1R1 for the Modulation of Neuroinflammation in Central Nervous System Disorders. Luís JP, Simões CJV, Brito RMM.
Int J Mol Sci. 2022 Feb 2;23(3):1731. doi: 10.3390/ijms23031731.
PMID: 35163653 Review.
25.
Differential Expression of Serum Extracellular Vesicle miRNAs in Multiple Sclerosis: Disease-Stage Specificity and Relevance to Pathophysiology. Cuomo-Haymour N, Bergamini G, Russo G, Kulic L, Knuesel I, Martin R, Huss A, Tumani H, Otto M, Pryce CR.
Int J Mol Sci. 2022 Jan 31;23(3):1664. doi: 10.3390/ijms23031664.
PMID: 35163583
26.
Identification of NLRP3PYD Homo-Oligomerization Inhibitors with Anti-Inflammatory Activity. Moasses Ghafary S, Soriano-Teruel PM, Lotfollahzadeh S, Sancho M, Serrano-Candelas E, Karami F, Barigye SJ, Fernández-Pérez I, Gozalbes R, Nikkhah M, Orzáez M, Hosseinkhani S.
Int J Mol Sci. 2022 Jan 31;23(3):1651. doi: 10.3390/ijms23031651.
PMID: 35163573
27.
Teriflunomide Preserves Neuronal Activity and Protects Mitochondria in Brain Slices Exposed to Oxidative Stress. Malla B, Liotta A, Bros H, Ulshöfer R, Paul F, Hauser AE, Niesner R, Infante-Duarte C.
Int J Mol Sci. 2022 Jan 28;23(3):1538. doi: 10.3390/ijms23031538.
PMID: 35163469
28.
Genome Editing Using CRISPR-Cas9 and Autoimmune Diseases: A Comprehensive Review. Lee MH, Shin JI, Yang JW, Lee KH, Cha DH, Hong JB, Park Y, Choi E, Tizaoui K, Koyanagi A, Jacob L, Park S, Kim JH, Smith L.
Int J Mol Sci. 2022 Jan 25;23(3):1337. doi: 10.3390/ijms23031337.
PMID: 35163260 Review.
29.
Emerging Connections between Nuclear Pore Complex Homeostasis and ALS. Chandra S, Lusk CP.
Int J Mol Sci. 2022 Jan 25;23(3):1329. doi: 10.3390/ijms23031329.
PMID: 35163252 Review.
30.
Vesicle Fusion as a Target Process for the Action of Sphingosine and Its Derived Drugs. Villanueva J, Gimenez-Molina Y, Davletov B, Gutiérrez LM.
Int J Mol Sci. 2022 Jan 19;23(3):1086. doi: 10.3390/ijms23031086.
PMID: 35163009 Review.
31.
Use of Prescribed Drugs to Treat Chronic Diseases during Pregnancy in Outpatient Care in Switzerland between 2014 and 2018: Descriptive Analysis of Swiss Health Care Claims Data. Gerbier E, Graber SM, Rauch M, Marxer CA, Meier CR, Baud D, Winterfeld U, Blozik E, Surbek D, Spoendlin J, Panchaud A.
Int J Environ Res Public Health. 2022 Jan 27;19(3):1456. doi: 10.3390/ijerph19031456.
PMID: 35162474
32.
Inertial Sensor Algorithm to Estimate Walk Distance. Shah VV, Curtze C, Sowalsky K, Arpan I, Mancini M, Carlson-Kuhta P, El-Gohary M, Horak FB, McNames J.
Sensors (Basel). 2022 Jan 29;22(3):1077. doi: 10.3390/s22031077.
PMID: 35161822
33.
Oligoclonal Band Straightening Based on Optimized Hierarchical Warping for Multiple Sclerosis Diagnosis. Haddad F, Boudet S, Peyrodie L, Vandenbroucke N, Poupart J, Hautecoeur P, Chieux V, Forzy G.
Sensors (Basel). 2022 Jan 18;22(3):724. doi: 10.3390/s22030724.
PMID: 35161470
34.
Therapeutic Effects of the Pilates Method in Patients with Multiple Sclerosis: A Systematic Review. Rodríguez-Fuentes G, Silveira-Pereira L, Ferradáns-Rodríguez P, Campo-Prieto P.
J Clin Med. 2022 Jan 28;11(3):683. doi: 10.3390/jcm11030683.
PMID: 35160134 Review.
35.
Mental Health Status of People with Multiple Sclerosis during the COVID-19 Pandemic. Wilski M, Koper M, Gabryelski J, Brola W, Tasiemski T.
J Clin Med. 2022 Jan 24;11(3):576. doi: 10.3390/jcm11030576.
PMID: 35160029
36.
Reflex Locomotion Therapy for Balance, Gait, and Fatigue Rehabilitation in Subjects with Multiple Sclerosis. Carratalá-Tejada M, Cuesta-Gómez A, Ortiz-Gutiérrez R, Molina-Rueda F, Luna-Oliva L, Miangolarra-Page JC.
J Clin Med. 2022 Jan 23;11(3):567. doi: 10.3390/jcm11030567.
PMID: 35160020
37.
Brain Volume Loss Can Occur at the Rate of Normal Aging in Patients with Multiple Sclerosis Who Are Free from Disease Activity. Temmerman J, Van Der Veken F, Engelborghs S, Guldolf K, Nagels G, Smeets D, Allemeersch GJ, Costers L, D’hooghe MB, Vanbinst AM, Van Schependom J, Bjerke M, D’haeseleer M.
J Clin Med. 2022 Jan 20;11(3):523. doi: 10.3390/jcm11030523.
PMID: 35159972
38.
Glycomic and Glycoproteomic Techniques in Neurodegenerative Disorders and Neurotrauma: Towards Personalized Markers. Kobeissy F, Kobaisi A, Peng W, Barsa C, Goli M, Sibahi A, El Hayek S, Abdelhady S, Ali Haidar M, Sabra M, Orešič M, Logroscino G, Mondello S, Eid AH, Mechref Y.
Cells. 2022 Feb 8;11(3):581. doi: 10.3390/cells11030581.
PMID: 35159390 Review.
39.
ISG15 and ISGylation in Human Diseases. Mirzalieva O, Juncker M, Schwartzenburg J, Desai S.
Cells. 2022 Feb 4;11(3):538. doi: 10.3390/cells11030538.
PMID: 35159348 Review.
40.
Polypharmacological Approaches for CNS Diseases: Focus on Endocannabinoid Degradation Inhibition. Papa A, Pasquini S, Contri C, Gemma S, Campiani G, Butini S, Varani K, Vincenzi F.
Cells. 2022 Jan 29;11(3):471. doi: 10.3390/cells11030471.
PMID: 35159280 Review.
41.
A Distinct Hibiscus sabdariffa Extract Prevents Iron Neurotoxicity, a Driver of Multiple Sclerosis Pathology. Mishra MK, Wang J, Mirzaei R, Chan R, Melo H, Zhang P, Ling CC, Bruccoleri A, Tang L, Yong VW.
Cells. 2022 Jan 27;11(3):440. doi: 10.3390/cells11030440.
PMID: 35159249
42.
Existing Evidence for the Repurposing of PARP-1 Inhibitors in Rare Demyelinating Diseases. Mekhaeil M, Dev KK, Conroy MJ.
Cancers (Basel). 2022 Jan 29;14(3):687. doi: 10.3390/cancers14030687.
PMID: 35158955 Review.
43.
B-cell depleters attenuate the humoral response to SARS-CoV-2 vaccines in multiple sclerosis patients: A case-control study. Conte WL.
Mult Scler Relat Disord. 2022 Jan;57:103413. doi: 10.1016/j.msard.2021.103413. Epub 2021 Nov 18.
PMID: 35158480 Free PMC article.
44.
Effect of desire for pregnancy on decisions to escalate treatment in multiple sclerosis care: Differences between MS specialists and non-MS specialists. Saposnik G, Andhavarapu S, Fernández Ó, Kim HJ, Wiendl H, Foss M, Zuo F, Havrdová EK, Celius EG, Caceres F, Magyari M, Bermel R, Costa A, Terzaghi M, Kalincik T, Popescu V, Amato MP, Montalban X, Oh J.
Mult Scler Relat Disord. 2022 Jan;57:103389. doi: 10.1016/j.msard.2021.103389. Epub 2021 Nov 13.
PMID: 35158479
45.
A web-based life-style, exercise and activity intervention for people with progressive multiple sclerosis: Results of a single-arm feasibility study. Busse M, Playle R, Latchem-Hastings J, Button K, Lowe R, Barlow C, Lloyd B, Dean-Young A, Poile V, Dawes H, Davies F, O’Halloran R, Tallantyre E, Edwards A, Wood F, Jones F.
Mult Scler Relat Disord. 2022 Jan;57:103388. doi: 10.1016/j.msard.2021.103388. Epub 2021 Nov 8.
PMID: 35158478
46.
Relationship between lymphopenia and disease activity in persons with multiple sclerosis treated with dimethyl fumarate. Chu L, Balusha A, Casserly C, Berger W, Morrow SA.
Mult Scler Relat Disord. 2022 Jan;57:103384. doi: 10.1016/j.msard.2021.103384. Epub 2021 Nov 8.
PMID: 35158477
47.
Treatment satisfaction, safety, and tolerability of cladribine tablets in patients with highly active relapsing multiple sclerosis: CLARIFY-MS study 6-month interim analysis. Brochet B, Hupperts R, Langdon D, Solari A, Piehl F, Lechner-Scott J, Montalban X, Selmaj K, Valis M, Rejdak K, Havrdova EK, Patti F, Alexandri N, Nolting A, Keller B.
Mult Scler Relat Disord. 2022 Jan;57:103385. doi: 10.1016/j.msard.2021.103385. Epub 2021 Nov 9.
PMID: 35158476
48.
Humoral and T-cell responses to SARS-CoV-2 vaccination in multiple sclerosis patients treated with ocrelizumab. Katz JD, Bouley AJ, Jungquist RM, Douglas EA, O’Shea IL, Lathi ES.
Mult Scler Relat Disord. 2022 Jan;57:103382. doi: 10.1016/j.msard.2021.103382. Epub 2021 Nov 9.
PMID: 35158475 Free PMC article.
49.
¿ Can COVID-19 exacerbate multiple sclerosis symptoms? A case series analysis. Michelena G, Casas M, Eizaguirre MB, Pita MC, Cohen L, Alonso R, Garcea O, Silva BA.
Mult Scler Relat Disord. 2022 Jan;57:103368. doi: 10.1016/j.msard.2021.103368. Epub 2021 Nov 3.
PMID: 35158474
50.
Early treatment responses to peginterferon beta-1a are associated with longer-term clinical outcomes in patients with relapsing-remitting multiple sclerosis: Subgroup analyses of ADVANCE and ATTAIN. Newsome SD, Scott TF, Arnold DL, Altincatal A, Naylor ML.
Mult Scler Relat Disord. 2022 Jan;57:103367. doi: 10.1016/j.msard.2021.103367. Epub 2021 Nov 3.
PMID: 35158473

2022 February 14
1.
Spontaneous remyelination in lesions protects the integrity of surrounding tissues over time in multiple sclerosis. Ricigliano VAG, Tonietto M, Hamzaoui M, Poirion É, Lazzarotto A, Bottlaender M, Gervais P, Maillart E, Stankoff B, Bodini B.
Eur J Neurol. 2022 Feb 12. doi: 10.1111/ene.15285. Online ahead of print.
PMID: 35152511
2.
Nutritional status in patients with advanced-stage multiple sclerosis. Teng M, Bensmail D, Hanachi M, Haddad R, Hugeron C, Lansaman T, Levy J.
Eur J Neurol. 2022 Feb 12. doi: 10.1111/ene.15286. Online ahead of print.
PMID: 35152502
3.
Amino Acid Solute Carrier Transporters in Inflammation and Autoimmunity. Sheng L, Luo Q, Chen L.
Drug Metab Dispos. 2022 Feb 12:DMD-AR-2021-000705. doi: 10.1124/dmd.121.000705. Online ahead of print.
PMID: 35152203
4.
The elimination of circulating Epstein-Barr virus infected B cells underlies anti-CD20 monoclonal antibody activity in multiple sclerosis: A hypothesis. Berger JR, Kakara M.
Mult Scler Relat Disord. 2022 Feb 7;59:103678. doi: 10.1016/j.msard.2022.103678. Online ahead of print.
PMID: 35151986
5.
Association between microglial activation and serum kynurenine pathway metabolites in multiple sclerosis patients. Saraste M, Matilainen M, Rajda C, Galla Z, Sucksdorff M, Vécsei L, Airas L.
Mult Scler Relat Disord. 2022 Feb 4;59:103667. doi: 10.1016/j.msard.2022.103667. Online ahead of print.
PMID: 35151985
6.
Salivary biomarkers of neurodegenerative and demyelinating diseases and biosensors for their detection. Goldoni R, Dolci C, Boccalari E, Inchingolo F, Paghi A, Strambini L, Galimberti D, Tartaglia GM.
Ageing Res Rev. 2022 Feb 10:101587. doi: 10.1016/j.arr.2022.101587. Online ahead of print.
PMID: 35151849 Review.
2022 February 13
1.
Incidence, prevalence, and characteristics of heart failure among patients with multiple sclerosis: A systematic review and meta-analysis. Bagherieh S, Ghoshouni H, Bostan F, Afshari-Safavi A, Badihian S, Barzegar M, Shaygannejad V, Mirmosayyeb O.
Mult Scler Relat Disord. 2022 Feb 4;59:103665. doi: 10.1016/j.msard.2022.103665. Online ahead of print.
PMID: 35150980 Review.
2.
Early predictive risk factors for dimethyl fumarate-associated lymphopenia in patients with multiple sclerosis. Sainz de la Maza S, Sabin Muñoz J, Pilo de la Fuente B, Thuissard I, Andreu-Vázquez C, Galán Sánchez-Seco V, Salgado-Cámara P, Costa-Frossard L, Monreal E, Ayuso-Peralta L, García-Vasco L, García-Domínguez JM, Martínez-Ginés ML, Muñoz Fernández C, Díaz-Díaz J, Oreja-Guevara C, Gómez-Moreno M, Martín H, Rubio-Flores L, Blasco MR, Villar-Guimerans LM, Aladro Y; Dimethyl Fumarate Study Group.
Mult Scler Relat Disord. 2022 Feb 4;59:103669. doi: 10.1016/j.msard.2022.103669. Online ahead of print.
PMID: 35150979
3.
A national, multi-center study in Germany to assess implementation of infusion management, treatment satisfaction and quality of life in MS patients receiving alemtuzumab. Räuber S, Pawlitzki M, Korsen M, Kullmann JS, Thoene D, Pfeuffer S, Rolfes L, Nelke C, Melzer N, Ruck T, Meuth SG; INFUSE-MS study group.
Mult Scler Relat Disord. 2022 Feb 5;59:103670. doi: 10.1016/j.msard.2022.103670. Online ahead of print.
PMID: 35150978
4.
Epidemiology of Pharmacological Treatment of Multiple Sclerosis in Croatia. Tomasović S, Košćak Lukač J, Sremec J, Klepac N, Draganić P, Bielen I.
Psychiatr Danub. 2021 Dec;33(Suppl 13):204-208.
PMID: 35150487
5.
Cognitive Aspects in Multiple Sclerosis. Lisak M, Špiljak B, Pašić H, Trkanjec Z.
Psychiatr Danub. 2021 Dec;33(Suppl 13):177-182.
PMID: 35150483
6.
Cognitive impairment and markers of optical neurodegeneration in early multiple sclerosis. Silva R, Coelho P, Seabra M, Laranjinha I, Vieira D, Costa O, Jesus J, Fonseca AC, Costa S, Ferreira I, Lemos J, Sousa C, Vale J, Sá MJ, Ruano L.
Neurol Sci. 2022 Feb 12. doi: 10.1007/s10072-022-05945-9. Online ahead of print.
PMID: 35150351
7.
The efficacy of speed of processing training for improving processing speed in individuals with multiple sclerosis: a randomized clinical trial. Chiaravalloti ND, Costa SL, Moore NB, Costanza K, DeLuca J.
J Neurol. 2022 Feb 12. doi: 10.1007/s00415-022-10980-9. Online ahead of print.
PMID: 35150301
8.
Comparing natural history of early and late onset pediatric multiple sclerosis. De Meo E, Filippi M, Trojano M, Comi G, Patti F, Brescia Morra V, Salemi G, Onofrj M, Lus G, Cocco E, Fonderico M, Torri Clerici V, Maniscalco GT, Valentino P, Bertolotto A, Lugaresi A, Bergamaschi R, Rovaris M, Sola P, Tedeschi G, Pesci I, Aguglia U, Cavalla P, Maimone D, Granella F, Vianello M, Simone M, Portaccio E, Amato MP.
Ann Neurol. 2022 Feb 12. doi: 10.1002/ana.26322. Online ahead of print.
PMID: 35150168
9.
Anti-Neuronal Nuclear Antibody 3 Autoimmunity targets Dachshund homolog 1. Zekeridou A, Yang B, Lennon VA, Guo Y, Wu L, Lucchinetti CF, McKeon A, Pittock SJ, Flanagan EP.
Ann Neurol. 2022 Feb 12. doi: 10.1002/ana.26320. Online ahead of print.
PMID: 35150165
2022 February 12
1.
Long-Term Effectiveness, Safety and Tolerability of Fingolimod in Patients with Multiple Sclerosis in Real-World Treatment Settings in France: The VIRGILE Study. Papeix C, Castelnovo G, Leray E, Coustans M, Levy P, Visy JM, Kobelt G, Lamy F, Allaf B, Heintzmann F, Chouette I, Raponi E, Durand B, Grevat E, Kamar D, Debouverie M, Lebrun-Frenay C; Virgile Study Group.
Neurol Ther. 2022 Feb 11. doi: 10.1007/s40120-022-00334-y. Online ahead of print.
PMID: 35147904
2.
Vascular dysfunction and dyslipidemia in multiple sclerosis: are they correlated with disease duration and disability status? Boshra H, Awad M, Hussein M, Elyamani E.
Egypt Heart J. 2022 Feb 11;74(1):9. doi: 10.1186/s43044-022-00244-2.
PMID: 35147792
3.
The Innate Chronotoxicity hypothesis: an ubiquitous physiological flaw both unnoticed and inevitable. Could circadian rhythm be an evolutionary mismatch? Gasperoni F.
Clin Ter. 2022 Feb 7;173(1):67-78. doi: 10.7417/CT.2022.2395.
PMID: 35147650
4.
Detection of galanin receptors in the spinal cord in experimental autoimmune encephalomyelitis. Michalickova D, Kramarikova I, Ozturk HK, Kucera T, Vacik T, Hrncir T, Kutinova Canova N, Sima M, Slanar O.
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2022 Feb 11. doi: 10.5507/bp.2022.005. Online ahead of print.
PMID: 35147137
5.
The Role of Heparin and Glycocalyx in Blood-Brain Barrier Dysfunction. Yang R, Chen M, Zheng J, Li X, Zhang X.
Front Immunol. 2021 Dec 21;12:754141. doi: 10.3389/fimmu.2021.754141. eCollection 2021.
PMID: 34992593 Free PMC article. Review.
2022 February 11
1.
TRPMLs and TPCs: Targets for lysosomal storage and neurodegenerative disease therapy? Krogsaeter E, Rosato AS, Grimm C.
Cell Calcium. 2022 Feb 5;103:102553. doi: 10.1016/j.ceca.2022.102553. Online ahead of print.
PMID: 35144097
2.
Pelvic floor muscle training in multiple sclerosis patients with lower urinary tract dysfunction: A systematic review and meta-analysis. Kajbafvala M, Ashnagar Z, Lucio A, Firoozeh F, Salehi R, Pashazadeh F, Dadgoo M, Jafari H.
Mult Scler Relat Disord. 2022 Jan 29;59:103559. doi: 10.1016/j.msard.2022.103559. Online ahead of print.
PMID: 35144089 Review.
3.
Tyrphostin A9 protects axons in experimental autoimmune encephalomyelitis through activation of ERKs. Dai X, Wang Y, Li Y, Zhong Y, Pei M, Long J, Dong X, Chen YL, Wang Q, Wang G, Gold BG, Vandenbark AA, Neve KA, Offner H, Wang C.
Life Sci. 2022 Feb 7:120383. doi: 10.1016/j.lfs.2022.120383. Online ahead of print.
PMID: 35143827
4.
Sec13 promotes oligodendrocyte differentiation and myelin repair through autocrine pleiotrophin signaling. Liu Z, Yan M, Lei W, Jiang R, Dai W, Chen J, Wang C, Li L, Wu M, Nian X, Li D, Sun D, Lv X, Wang C, Xie C, Yao L, Wu C, Hu J, Xiao N, Mo W, Wang Z, Zhang L.
J Clin Invest. 2022 Feb 10:e155096. doi: 10.1172/JCI155096. Online ahead of print.
PMID: 35143418
5.
Is Mediterranean diet associated with multiple sclerosis related symptoms and fatigue severity? Ertaş Öztürk Y, Helvaci EM, Sökülmez Kaya P, Terzi M.
Nutr Neurosci. 2022 Feb 10:1-7. doi: 10.1080/1028415X.2022.2034241. Online ahead of print.
PMID: 35143375
6.
Optimizing EEG Source Reconstruction with Concurrent fMRI-Derived Spatial Priors. Abreu R, Soares JF, Lima AC, Sousa L, Batista S, Castelo-Branco M, Duarte JV.
Brain Topogr. 2022 Feb 10. doi: 10.1007/s10548-022-00891-3. Online ahead of print.
PMID: 35142957
7.
Natalizumab treatment during pregnancy in multiple sclerosis-clinical and bioethical aspects of an ongoing debate. Berek K, Paganini C, Hegen H, Bsteh G, Grams A, Auer M, Berger T, Deisenhammer F, Di Pauli F.
Wien Med Wochenschr. 2022 Feb 10. doi: 10.1007/s10354-022-00913-6. Online ahead of print.
PMID: 35142953
8.
Is there a window of opportunity for the therapeutic use of vitamin D in multiple sclerosis? Zorzella-Pezavento SFG, Mimura LAN, Denadai MB, de Souza WDF, Fraga-Silva TFC, Sartori A.
Neural Regen Res. 2022 Sep;17(9):1945-1954. doi: 10.4103/1673-5374.335139.
PMID: 35142671 Review.
9.
Cortical lesion hotspots and association of subpial lesions with disability in multiple sclerosis. Beck ES, Maranzano J, Luciano NJ, Parvathaneni P, Filippini S, Morrison M, Suto DJ, Wu T, van Gelderen P, de Zwart JA, Antel S, Fetco D, Ohayon J, Andrada F, Mina Y, Thomas C, Jacobson S, Duyn J, Cortese I, Narayanan S, Nair G, Sati P, Reich DS.
Mult Scler. 2022 Feb 10:13524585211069167. doi: 10.1177/13524585211069167. Online ahead of print.
PMID: 35142571
10.
Diagnosis and genotype-phenotype correlation in patients with PKD1/TSC2 contiguous gene deletion syndrome. Shang S, Mei Y, Wang T, Zheng X, Chen K, Xiong S, Dong Y, Chang Y, Wu X, Kong X, Tan M, Wu L, Zhang Y, Xiao Y, Xie Y, Cai G, Chen X, Li Q.
Clin Nephrol. 2022 Feb 10. doi: 10.5414/CN110476. Online ahead of print.
PMID: 35142283
11.
Plasma microRNA vary in association with the progression of Alzheimer’s disease. Guévremont D, Tsui H, Knight R, Fowler CJ, Masters CL, Martins RN, Abraham WC, Tate WP, Cutfield NJ, Williams JM.
Alzheimers Dement (Amst). 2022 Feb 5;14(1):e12251. doi: 10.1002/dad2.12251. eCollection 2022.
PMID: 35141392 Free PMC article.
12.
First Wave of COVID-19 Pandemic in Italy: Data and Evidence. Bezzini D, Schiavetti I, Manacorda T, Franzone G, Battaglia MA.
Adv Exp Med Biol. 2021;1353:91-113. doi: 10.1007/978-3-030-85113-2_6.
PMID: 35137370
13.
Unusual primary central nervous system T-cell/histiocyte-rich large B-cell lymphoma: a case report. Toro J, Patiño J, Flórez A, Rivera JS.
BMJ Case Rep. 2022 Feb 8;15(2):e246355. doi: 10.1136/bcr-2021-246355.
PMID: 35135790
14.
Asymmetric alterations of white matter integrity in patients with insomnia disorder. Rostampour M, Gharaylou Z, Rostampour N, Kaveh D, Noori K, Fadaei R, Tahmasian M, Khazaie H, Zarei M.
Brain Imaging Behav. 2022 Feb;16(1):389-396. doi: 10.1007/s11682-021-00512-w. Epub 2021 Aug 24.
PMID: 34427878
15.
Neural correlates of extrinsic and intrinsic outcome processing during learning in individuals with TBI: a pilot investigation. Dobryakova E, Zuckerman S, Sandry J.
Brain Imaging Behav. 2022 Feb;16(1):344-354. doi: 10.1007/s11682-021-00508-6. Epub 2021 Aug 18.
PMID: 34406636
16.
Gastric Cancer Diagnosis: From Imaging Techniques to Biochemical Biomarkers. Tavakoli F, Khatami SS, Momeni F, Azadbakht J, Ghasemi F.
Curr Mol Med. 2021;21(5):355-375. doi: 10.2174/1566524020666200905115100.
PMID: 32888267 Review.